275 related articles for article (PubMed ID: 15801925)
1. A randomized, double blind, comparative trial of micafungin (FK463) vs. fluconazole for the treatment of oesophageal candidiasis.
de Wet NT; Bester AJ; Viljoen JJ; Filho F; Suleiman JM; Ticona E; Llanos EA; Fisco C; Lau W; Buell D
Aliment Pharmacol Ther; 2005 Apr; 21(7):899-907. PubMed ID: 15801925
[TBL] [Abstract][Full Text] [Related]
2. A randomized, double-blind, parallel-group, dose-response study of micafungin compared with fluconazole for the treatment of esophageal candidiasis in HIV-positive patients.
de Wet N; Llanos-Cuentas A; Suleiman J; Baraldi E; Krantz EF; Della Negra M; Diekmann-Berndt H
Clin Infect Dis; 2004 Sep; 39(6):842-9. PubMed ID: 15472817
[TBL] [Abstract][Full Text] [Related]
3. Successful treatment of oesophageal candidiasis by micafungin: a novel systemic antifungal agent.
Pettengell K; Mynhardt J; Kluyts T; Lau W; Facklam D; Buell D;
Aliment Pharmacol Ther; 2004 Aug; 20(4):475-81. PubMed ID: 15298643
[TBL] [Abstract][Full Text] [Related]
4. Micafungin versus caspofungin for treatment of candidemia and other forms of invasive candidiasis.
Pappas PG; Rotstein CM; Betts RF; Nucci M; Talwar D; De Waele JJ; Vazquez JA; Dupont BF; Horn DL; Ostrosky-Zeichner L; Reboli AC; Suh B; Digumarti R; Wu C; Kovanda LL; Arnold LJ; Buell DN
Clin Infect Dis; 2007 Oct; 45(7):883-93. PubMed ID: 17806055
[TBL] [Abstract][Full Text] [Related]
5. Micafungin versus liposomal amphotericin B for pediatric patients with invasive candidiasis: substudy of a randomized double-blind trial.
Queiroz-Telles F; Berezin E; Leverger G; Freire A; van der Vyver A; Chotpitayasunondh T; Konja J; Diekmann-Berndt H; Koblinger S; Groll AH; Arrieta A;
Pediatr Infect Dis J; 2008 Sep; 27(9):820-6. PubMed ID: 18679151
[TBL] [Abstract][Full Text] [Related]
6. A randomized, double-blind trial of anidulafungin versus fluconazole for the treatment of esophageal candidiasis.
Krause DS; Simjee AE; van Rensburg C; Viljoen J; Walsh TJ; Goldstein BP; Wible M; Henkel T
Clin Infect Dis; 2004 Sep; 39(6):770-5. PubMed ID: 15472806
[TBL] [Abstract][Full Text] [Related]
7. A study to determine the safety profile and maximum tolerated dose of micafungin (FK463) in patients undergoing haematopoietic stem cell transplantation.
Sirohi B; Powles RL; Chopra R; Russell N; Byrne JL; Prentice HG; Potter M; Koblinger S
Bone Marrow Transplant; 2006 Jul; 38(1):47-51. PubMed ID: 16715107
[TBL] [Abstract][Full Text] [Related]
8. Comparison of micafungin and fluconazole for experimental Candida keratitis in rabbits.
Hiraoka T; Kaji Y; Wakabayashi T; Nanbu PN; Okamoto F; Oshika T
Cornea; 2007 Apr; 26(3):336-42. PubMed ID: 17413962
[TBL] [Abstract][Full Text] [Related]
9. Micafungin (Mycamine) for fungal infections.
Med Lett Drugs Ther; 2005 Jun; 47(1211):51-2. PubMed ID: 15961968
[TBL] [Abstract][Full Text] [Related]
10. Micafungin plus fluconazole in an infected knee with retained hardware due to Candida albicans.
Bland CM; Thomas S
Ann Pharmacother; 2009 Mar; 43(3):528-31. PubMed ID: 19261955
[TBL] [Abstract][Full Text] [Related]
11. Single-dose fluconazole versus standard 2-week therapy for oropharyngeal candidiasis in HIV-infected patients: a randomized, double-blind, double-dummy trial.
Hamza OJ; Matee MI; Brüggemann RJ; Moshi MJ; Simon EN; Mugusi F; Mikx FH; van der Lee HA; Verweij PE; van der Ven AJ
Clin Infect Dis; 2008 Nov; 47(10):1270-6. PubMed ID: 18840077
[TBL] [Abstract][Full Text] [Related]
12. A randomized, double-blind, double-dummy, multicenter trial of voriconazole and fluconazole in the treatment of esophageal candidiasis in immunocompromised patients.
Ally R; Schürmann D; Kreisel W; Carosi G; Aguirrebengoa K; Dupont B; Hodges M; Troke P; Romero AJ;
Clin Infect Dis; 2001 Nov; 33(9):1447-54. PubMed ID: 11577374
[TBL] [Abstract][Full Text] [Related]
13. Fluconazole vs. flucytosine in the treatment of esophageal candidiasis in AIDS patients: a double-blind, placebo-controlled study.
Barbaro G; Barbarini G; Di Lorenzo G
Endoscopy; 1995 Jun; 27(5):377-83. PubMed ID: 7588352
[TBL] [Abstract][Full Text] [Related]
14. Efficacy and safety of micafungin for treatment of serious Candida infections in patients with or without malignant disease.
Cornely OA; Marty FM; Stucker F; Pappas PG; Ullmann AJ
Mycoses; 2011 Nov; 54(6):e838-47. PubMed ID: 21668522
[TBL] [Abstract][Full Text] [Related]
15. Micafungin: a new echinocandin antifungal.
Joseph JM; Jain R; Danziger LH
Pharmacotherapy; 2007 Jan; 27(1):53-67. PubMed ID: 17192162
[TBL] [Abstract][Full Text] [Related]
16. The pharmacokinetics and safety of micafungin, a novel echinocandin, in premature infants.
Heresi GP; Gerstmann DR; Reed MD; van den Anker JN; Blumer JL; Kovanda L; Keirns JJ; Buell DN; Kearns GL
Pediatr Infect Dis J; 2006 Dec; 25(12):1110-5. PubMed ID: 17133155
[TBL] [Abstract][Full Text] [Related]
17. Anidulafungin versus fluconazole for invasive candidiasis.
Reboli AC; Rotstein C; Pappas PG; Chapman SW; Kett DH; Kumar D; Betts R; Wible M; Goldstein BP; Schranz J; Krause DS; Walsh TJ;
N Engl J Med; 2007 Jun; 356(24):2472-82. PubMed ID: 17568028
[TBL] [Abstract][Full Text] [Related]
18. Safety and efficacy of micafungin in transplantation recipients.
Forrest GN; Rasetto F; Akpek G; Philosophe B
Transplantation; 2006 Dec; 82(11):1549. PubMed ID: 17164733
[No Abstract] [Full Text] [Related]
19. A multicenter, open-label clinical study of micafungin (FK463) in the treatment of deep-seated mycosis in Japan.
Kohno S; Masaoka T; Yamaguchi H; Mori T; Urabe A; Ito A; Niki Y; Ikemoto H
Scand J Infect Dis; 2004; 36(5):372-9. PubMed ID: 15287383
[TBL] [Abstract][Full Text] [Related]
20. Efficacy of micafungin against deep-seated candidiasis in cyclophosphamide-induced immunosuppressed mice.
Ninomiya M; Mikamo H; Tanaka K; Watanabe K; Tamaya T
J Antimicrob Chemother; 2005 Apr; 55(4):587-90. PubMed ID: 15728144
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
